Diagnosis and treatment of pulmonary arterial hypertension: a review
NF Ruopp, BA Cockrill - Jama, 2022 - jamanetwork.com
Importance Pulmonary arterial hypertension (PAH) is a subtype of pulmonary hypertension
(PH), characterized by pulmonary arterial remodeling. The prevalence of PAH is …
(PH), characterized by pulmonary arterial remodeling. The prevalence of PAH is …
[HTML][HTML] Risk stratification and medical therapy of pulmonary arterial hypertension
N Galiè, RN Channick, RP Frantz… - European …, 2019 - Eur Respiratory Soc
Pulmonary arterial hypertension (PAH) remains a severe clinical condition despite the
availability over the past 15 years of multiple drugs interfering with the endothelin, nitric …
availability over the past 15 years of multiple drugs interfering with the endothelin, nitric …
An overview of the 6th World Symposium on Pulmonary Hypertension
Since 1973 the World Symposia on Pulmonary Hypertension (WSPH) proceedings have
summarised the scientific advances and future needs in this field through the efforts of …
summarised the scientific advances and future needs in this field through the efforts of …
Sources of vascular nitric oxide and reactive oxygen species and their regulation
J Tejero, S Shiva, MT Gladwin - Physiological reviews, 2019 - journals.physiology.org
Nitric oxide (NO) is a small free radical with critical signaling roles in physiology and
pathophysiology. The generation of sufficient NO levels to regulate the resistance of the …
pathophysiology. The generation of sufficient NO levels to regulate the resistance of the …
Update of EULAR recommendations for the treatment of systemic sclerosis
O Kowal-Bielecka, J Fransen, J Avouac… - Annals of the …, 2017 - ard.bmj.com
The aim was to update the 2009 European League against Rheumatism (EULAR)
recommendations for the treatment of systemic sclerosis (SSc), with attention to new …
recommendations for the treatment of systemic sclerosis (SSc), with attention to new …
[HTML][HTML] Development and validation of an abridged version of the REVEAL 2.0 risk score calculator, REVEAL Lite 2, for use in patients with pulmonary arterial …
RL Benza, MK Kanwar, A Raina, JV Scott, CL Zhao… - Chest, 2021 - Elsevier
Background Achievement of low-risk status is a treatment goal in pulmonary arterial
hypertension (PAH). Risk assessment often is performed using multiparameter tools, such …
hypertension (PAH). Risk assessment often is performed using multiparameter tools, such …
Pulmonary arterial hypertension: pathogenesis and clinical management
Pulmonary hypertension is defined as a resting mean pulmonary artery pressure of 25 mm
Hg or above. This review deals with pulmonary arterial hypertension (PAH), a type of …
Hg or above. This review deals with pulmonary arterial hypertension (PAH), a type of …
Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis
MM Hoeper, K Dwivedi, C Pausch… - The Lancet …, 2022 - thelancet.com
Background Among patients meeting diagnostic criteria for idiopathic pulmonary arterial
hypertension (IPAH), there is an emerging lung phenotype characterised by a low diffusion …
hypertension (IPAH), there is an emerging lung phenotype characterised by a low diffusion …
2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of …
Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple
clinical conditions and can complicate the majority of cardiovascular and respiratory …
clinical conditions and can complicate the majority of cardiovascular and respiratory …
[PDF][PDF] 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
6.2. 2. Wydolność wysiłkowa......................... 1147 6.2. 3. Markery biochemiczne........................
1147 6.2. 4. Kompleksowa ocena rokownicza i oszacowanie ryzyka........................... 1148 6.2 …
1147 6.2. 4. Kompleksowa ocena rokownicza i oszacowanie ryzyka........................... 1148 6.2 …